Acute hemolysis after receiving oxaliplatin treatment: a case report and literature review

Lai, Jiun-I; Wang, Wei Shu

doi:10.1007/s11096-009-9313-0

Cited by 12 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, because we required at least three exposed cases for our case‐control analysis of the outpatient cases and one case of oxaliplatin‐induced IHA had developed in hospital, we could not further evaluate the risk for this drug in the case‐control analysis. At least 15 cases of oxaliplatin‐associated IHA have been published in the literature (Koutras et al , 2004; Cobo et al , 2007; Arndt et al , 2009; Lai & Wang, 2009). Oxaliplatin‐dependent RBC antibodies have been detected in a number of these cases and were summarized by Arndt et al (2009).…”

Section: Discussionmentioning

confidence: 99%

Drug induced immune haemolytic anaemia in the Berlin Case‐Control Surveillance Study

et al. 2011

View full text Add to dashboard Cite

Summary Drug‐induced immune haemolytic anaemia is a rare but serious condition. This study investigated the possibility of drug aetiology of immune haemolytic anaemia (IHA) in 134 patients with new onset of IHA who were identified in the Berlin Case‐Control Surveillance Study between 2000 and 2009. Single drugs related to IHA in three or more patients and assessed more than once as a certain or probable cause of IHA in a standardized causality assessment included diclofenac, fludarabine, oxaliplatin, ceftriaxone and piperacillin. In a case‐control study including all 124 IHA cases developed in outpatient care and 731 controls, significantly increased odds ratios (OR) were observed for beta‐lactam antibiotics (OR = 8·8; 95% confidence interval [CI] 3·2–25·2), cotrimoxazole (OR = 6·5; CI 1·1–37·9), ciprofloxacin (OR = 6·9, CI 1·3–38·5), fludarabine (OR = 22·2; CI: 2·8–454·5) and lorazepam (OR = 5·3; CI: 1·2–21·2). Excluding new onset cases with a chronic IHA disease course, an increased risk became also apparent for diclofenac with an OR of 3·1 (CI 1·3–7·0). This is the first case‐control study investigating drugs as risk factors for IHA. It corroborates an increased risk for several drugs that have been implicated as a cause of IHA in the standardized causality assessment of individual cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug induced immune haemolytic anaemia in the Berlin Case‐Control Surveillance Study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…This event has never been described in the course of a first administration of oxaliplatin. The earliest case occurred at the 4th session [3] but the patient had been receiving globular transfusions since the 2nd session. Hemolysis always resolved after stopping administration of the molecule.…”

Section: Discussionmentioning

confidence: 99%

Recurrent Oxaliplatin-Induced Immune Hemolytic Anemia by Chemotherapy for Metastatic Colon Cancer: A Case Report

Oziel-Taïeb¹,

Sabatier²,

Gilabert³

et al. 2013

JCT

View full text Add to dashboard Cite

We report herein the case of a 55-year-old man who presented an acute hemolysis following a 6th cycle of FOLFOX regimen for a metastatic colorectal cancer; this patient had previously received 12 cycles in an adjuvant setting. He had presented attenuated signs during the previous cycle. This corresponded to an oxaliplatin-induced immune hemolytic anemia. This unfrequent side effect of oxaliplatin needs to be known in order to avoid severe complications.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Acute hemolysis after receiving oxaliplatin treatment: a case report and literature review

Abstract: Oxaliplatin related hemolytic anemia is a rare reported phenomenon. Patient under oxaliplatin treatment presenting with sudden hemoglobin decrease should prompt further investigation of hemolysis.

Cited by 12 publications

References 10 publications

Drug induced immune haemolytic anaemia in the Berlin Case‐Control Surveillance Study

Drug induced immune haemolytic anaemia in the Berlin Case‐Control Surveillance Study

Recurrent Oxaliplatin-Induced Immune Hemolytic Anemia by Chemotherapy for Metastatic Colon Cancer: A Case Report

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About